Neratinib for Breast Cancer
This trial is testing neratinib, pertuzumab, trastuzumab, and paclitaxel as possible treatments for metastatic breast cancer.
- Stage III Breast Cancer
- Stage IV Breast Cancer
- Inflammatory Breast Cancer
- Breast Cancer
- Metastatic Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 1 & 2 trial • 49 Patients • NCT02236000
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Has any other research been conducted on Neratinib?
"Currently, there are 1893 independent investigations into Neratinib with 423 of them in their terminal phase. Most of the trials take place in Seattle, Washington but they span 79307 different sites across the globe."
Is the enrollment process for this experiment still open?
"Currently, this study is no longer accepting participants. This investigation was initially posted on January 29th 2018 and had its latest update on July 13th 2022. If you are searching for alternate trials, 4568 studies related to inflammatory breast neoplasms and 1893 clinical investigations concerning Neratinib are currently recruiting patients."
Is this investigation a pioneering endeavor?
"As of today, there are 1,893 live trials involving Neratinib spanning 86 countries and 3723 cities. The inaugural trial for this drug was sponsored by Alfacell in 1997; it included 300 participants and progressed up to its Phase 3 approval stage. Since then, an additional 3233 studies have been conducted on the medication."
How many volunteers are taking part in this medical experiment?
"At this time, participants are not being accepted into the clinical trial that was first launched in January of 2018 and last updated on July 13th 2022. If one wishes to explore other medical studies, there are currently 4568 trials actively recruiting patients with inflammatory breast neoplasms and 1893 for Neratinib-related treatments which require enrolment."